What we do
Pharmaceuticals with a difference
With a guiding principle of working to improve your health, we deliver pharmaceuticals that make a real difference to people’s health.
AFT is a growing multinational pharmaceutical company that develops, markets, and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories. Our diverse range of products includes both proprietary and in-licensed items, which are available in more than 85 countries worldwide.
We continue to invest in extending our global reach, expanding our product range, and adding new medicines to a research and development portfolio that promises better health outcomes for people around the world.
AFT Pharmaceuticals SA (Pty) Ltd (‘AFT SA’) was established in early 2025 as part of our global expansion strategy. Jointly owned by AFT Pharmaceuticals (70%) and Edge Pharmaceuticals (30%), AFT SA is able to leverage both companies’ pharmaceutical products as well as Edge’s international expertise in accessing markets.
Following its acquisition of the Hospital Division business of Pharma Dynamics (Pty) Ltd in October 2025, AFT SA now holds a SAHPRA[1] licence and offers a portfolio of more than 30 trusted hospital products. From 2026 onward, it will expand access to a growing range of globally marketed therapeutics for South African hospitals and the wider community.
More about our history here
“At AFT Pharmaceuticals, we remain committed to reinvest into R&D to help people across the world.”
Hartley Atkinson, Founder and Managing Director
South Africa Team
Deon Hall
Drew Hansen
Sanette Benecke
Sharon Jordaan
The Board
Our board members
David Flacks
Dr Hartley Atkinson
Marree Atkinson
Andrew Lane
Dr Ted Witek
Allison Yorston
Join our team
We’re always looking for talented people, please have a look at the careers we currently have available.
Latest news
Keep up to date with the latest news from AFT Pharmaceuticals
July 23, 2026
Pitt St Research initiates coverage on AFT Pharmaceuticals
AFT Pharmaceuticals (NZX: AFT; ASX: AFP), today announces that Pitt St Research has initiated coverage on AFT Pharmaceuticals Ltd….
May 21, 2026
AFT delivers double digit revenue growth and record earnings
Operating profit or $24.4 million ahead of the guidance range….
May 18, 2026
AFT Pharmaceuticals names Stuart Houliston CFO
AFT Pharmaceuticals (NZX: AFT; ASX: AFP), New Zealand’s largest domestic pharmaceuticals company, today advises that Stuart Houliston will commence …